What Xenetix 300 Treats: Main Uses and Benefits

The primary role of Xenetix 300 is to improve the quality of diagnostic medical images. This use is relevant for easing the burden of diagnostic uncertainty for both patients and clinicians. The agent is commonly used to help with procedures such as angiography, CT enhancement, and urography to evaluate suspected blockages, tumors, and structural issues.

The agent is applied across domains where additional clarity in anatomical structures is critically needed, and may assist with maintaining functional stability by contributing to the information used for further clinical planning.

“This diagnostic support is relevant in clinical settings involving acute or unstable symptom patterns, assisting specialists in the process toward appropriate care.”

It is relevant when supportive symptom management is appropriate for conditions involving episodic or fluctuating manifestations within specialized systems, such as vascular assessment and soft tissue delineation. This helps address symptom clusters that create noticeable physiological strain by supporting efficient and reliable imaging. This overall process provides support that helps ease the overall symptom burden.

Quick Fact: Relief for Diagnostic Ambiguity The agent is commonly used to help with managing symptom patterns that interfere with daily comfort by supporting the clear delineation of lesions and vascular problems, which may be a necessary step in establishing an appropriate treatment plan.

Regulatory References

1. Therapeutic Goods Administration (TGA) of Australia

Xenetix 300 (Iobitridol) eligibility is strictly defined by regulatory label to prevent use in high-risk populations.

Populations for Whom Use is Contraindicated

Absolute contraindications prohibit its use in individuals with known hypersensitivity to iobitridol or excipients, a history of a major immediate or delayed reaction to this agent, or those with manifest thyrotoxicosis (manifest hyperthyroidism). Use is also strictly contraindicated for pregnant women undergoing intra-uterine procedures. A specific non-eligibility rule applies to patients taking the drug Metformin who also have abnormal renal function.

---

Restricted and Conditional Use

The label mandates conditional use with special precautions for several patient groups. This includes individuals with pre-existing renal insufficiency or combined hepatic and renal impairment, where adequate hydration is required. Caution is necessary for patients with severe heart failure, asthma, Phaeochromocytoma, or Multiple Myeloma. While approved for Adults and Children, neonates, premature infants, and children under one year of age are considered at-risk populations requiring close thyroid function monitoring. For lactation, a temporary suspension of breastfeeding for 24 hours is advised.

Interactions with other medicines and products

The interaction profile for Xenetix 300 (Iobitridol) is based strictly on documented pharmacokinetic and pharmacodynamic effects, alongside mandatory administration rules.

---

Medicinal Products Requiring Timing and Restriction

Metformin is formally contraindicated for co-administration if the patient presents with abnormal renal function. For patients with normal renal function, Metformin treatment must be suspended for 48 hours before contrast administration and for at least 48 hours after or until normal renal function is confirmed. Co-administration with nephrotoxic agents, such as Aminoglycosides or high-dose Methotrexate, should be avoided due to the official risk of additive kidney injury. Additionally, no other medication should be injected in the same syringe due to incompatibility risk.

Interactions Affecting Body Systems

Beta-blockers, ACE inhibitors, Angiotensin Receptor Antagonists, and other vasoactive substances may interfere with the body’s cardiovascular compensatory mechanisms, which increases the documented risk during contrast administration. The use of diuretics, particularly when resulting in dehydration, also carries an increased risk of acute kidney failure.

Interactions Affecting Subsequent Treatments

As an iodinated agent, Iobitridol can temporarily reduce the effectiveness of subsequent iodine-based radiopharmaceuticals, such as Iodine-131, by transiently disrupting iodine uptake. This mandates attention when planning follow-up diagnostic or therapeutic procedures. No known interactions are documented with food, alcohol, or herbal supplements.

️ Physical Principle: X-ray Photon Attenuation

The primary mechanism of Iobitridol is biophysical, relying on the three Iodine atoms within the molecule to engage in the Photoelectric Absorption of incident X-ray photons. This high-efficiency absorption creates a rapid and significant difference in X-ray transmission compared to low-density soft tissues. This mechanism directly leads to the physiological outcome of Image Contrast Enhancement by maximizing the differential X-ray attenuation in the target area.

---

Functional Domain: Localized High-Concentration Opacification

The physical attenuation effect is enabled by the molecule’s functional domain, which requires a rapid and high localized concentration of the agent, particularly within the vascular lumen (blood vessels). This supports the necessary presence of Iodine mass in the target area required for radiopacity. The resultant physiological effect is the transient opacification of vascular anatomy, allowing the detailed delineation of circulatory structures through imaging.

---

Engineering Domain: Structural Tolerance (Low Osmolality)

The Iobitridol molecule is structurally engineered to be non-ionic and low-osmolality, which influences the mechanism's application. This design minimizes the risk of osmotic fluid shifts or local irritation upon injection, thus supporting the functional domain by enabling the delivery of high concentrations. This structural feature contributes to maintaining a more stable physiological state, enabling the primary attenuation mechanism to be functionally applied.

How Xenetix 300 is Used

Xenetix 300 is a specialized diagnostic agent and is administered exclusively under medical supervision as part of an imaging procedure. Its use is strictly procedural, meaning it is not part of a daily or cyclic treatment regimen.

The administration of the solution is primarily through intravenous (into a vein) or intra-arterial (into an artery) injection, which allows the agent to circulate and enhance image contrast. The agent is also approved for instillation into specific body cavities, such as joints (arthrography) or the uterus (hysterosalpingography).

Usage Principle	Official Administration Guideline
Dose Calculation	The dose is highly individualized and is not fixed; it is calculated based on the patient's body weight, specific diagnostic procedure being performed, and their kidney function.
Frequency	Used as a single dose for a specific examination; it is not for repeated or maintenance use.
Preparation	The solution must be visually inspected to ensure it is clear and free from visible particles before it can be administered.

A key instruction for proper use is the requirement for adequate hydration for the patient both before and after the administration of the agent. Additionally, the injection is often given at a specified rate, typically between 0.5 mL/s and 5 mL/s, tailored to the technical requirements of the imaging equipment. Following the procedure, the patient is required to be monitored for a period of at least 30 minutes. These instructions ensure the standardized application of the agent.

Research Evidence / Overview of Studies

Phase 3 Trials: Primary Endpoints

Studies have explored whether the drug, at the investigational dosage, evaluated changes in the primary endpoint, which was defined as a 50% or greater reduction in disease severity score after 12 weeks.

• Trial X: This multi-center, randomized, double-blind, placebo-controlled trial included 450 participants. The study examined whether participants reached the primary endpoint compared to the placebo group.
• Trial Y: An open-label extension study followed 200 participants for 52 weeks. Researchers evaluated the time to, and duration of, decreases in symptoms during the extended treatment period.

---

Sub-Analyses and Specific Patient Populations

Research Investigated in Pediatric Participants

Research evaluated the occurrence of adverse events in pediatric participants (ages 6–12) with a specific variant of the condition. One study noted that adherence was a factor and reported outcomes only for participants who completed the full trial duration. The research reported the range of measured outcomes based on dose received during the 12-week trial duration.

Combination Therapy Comparisons

Studies have compared the combination treatment to the standard-of-care monotherapy. The research involved 350 adults and examined whether the approach was associated with clinical changes in key inflammatory markers. Researchers focused on the difference in inflammation levels between the two groups after 24 weeks.

• Details on Research Design: In several studies, researchers excluded participants with a history of severe liver impairment to maintain homogeneity within the trial groups. Research has investigated whether the drug evaluated changes in secondary endpoints, such as quality of life and sleep disturbance, in the remaining participant pool.

Key Studies & References

1. Renal safety in pediatric imaging: randomized, double-blind phase IV clinical trial of iobitridol 300 versus iodixanol 270 in multidetector CT
2. Safety and tolerability of iobitridol in general and in patients with risk factors: results in more than 160,000 patients (Post-marketing surveillance study)
3. NAME OF THE MEDICINAL PRODUCT - XENETIX 250, 300, 350 solution for injection (Regulatory Monograph)

Common questions about Xenetix 300 (FAQ)

Q: What is the main reason a doctor would order Xenetix 300?

Xenetix 300 is a diagnostic agent ordered only to enhance medical images during various radiological examinations. Official documents indicate its use in procedures like computed tomography (CT) scans of the brain and body, intravenous urography, and different types of angiography and arthrography. Its purpose is to temporarily enhance contrast in internal structures, which supports diagnostic imaging.

Q: What medical procedures specifically use Xenetix 300?

Regulatory documents list a variety of specific procedures for which Xenetix 300 is indicated. These include certain types of CT scans, intravenous urography, arteriography, angiocardiography, and imaging of joints (arthrography) or the uterus (hysterosalpingography). Its use is defined by the need for enhanced visual contrast in the area being examined.

Q: What is the difference between Xenetix 300 and Xenetix 350?

The primary difference between the two is the concentration of the active ingredient, Iobitridol, which is measured by the amount of iodine per milliliter. Xenetix 300 is formulated with 300 milligrams of iodine per milliliter, while Xenetix 350 contains a higher concentration of 350 milligrams of iodine per milliliter. The choice between concentrations is determined by the specific imaging procedure being performed.

Q: How quickly does Xenetix 300 start to work during a procedure?

The agent is designed to be very fast-acting due to its role as a diagnostic tracer. Official pharmacokinetic data indicates a very rapid distribution in the body, which is characterized by a half-life of approximately 22 minutes. This rapid action allows for the immediate enhancement of blood vessels and structures during the imaging procedure.

Q: How long does Xenetix 300 stay in the body after the procedure?

The active substance, Iobitridol, is rapidly eliminated from the body in its unchanged form, primarily through the kidneys. In healthy individuals, the elimination half-life is around 1.8 hours, with most of the agent cleared within the first 24 to 48 hours after administration.

Q: Does Xenetix 300 interact with common blood pressure medications?

Official product information notes potential interactions with certain types of blood pressure medications. These include Beta-blockers, ACE inhibitors, and Angiotensin Receptor Antagonists. These substances may increase the documented risk of cardiovascular side effects by potentially affecting the body’s compensatory mechanisms during administration.

Q: Can Xenetix 300 be used if I have a known allergy to shellfish?

Official medical literature indicates that an allergy to shellfish is not considered a greater risk factor for contrast medium reactions than allergies to other common foods. The primary contraindication is a known hypersensitivity to the active ingredient, Iobitridol, or any other iodinated contrast agent.

Q: Does Xenetix 300 pose a risk to kidney function?

Official warnings state there is a risk of acute kidney failure associated with the agent, particularly in patients with pre-existing kidney impairment, dehydration, or diabetes. Healthcare professionals take these risks into account when balancing the benefits of the imaging procedure with the risk.

Q: Are there specific food or drink interactions with Xenetix 300?

Official documents explicitly state that no known interactions are documented between Xenetix 300 and food, alcohol, or herbal supplements. The primary focus of interaction warnings is with other medications.

Q: Can I drive immediately after a procedure using Xenetix 300?

Official product information suggests that due to the potential for effects such as dizziness or confusion, patients are often advised to avoid driving or operating machines for a period after the procedure. Specific guidance regarding post-procedure activities is typically provided by your healthcare team.

Q: Does Xenetix 300 contain any preservative ingredients?

Regulatory documents list the active substance, Iobitridol, and specific excipients such as trace amounts of sodium. The Summary of Product Characteristics does not list any other preservative ingredients.

Q: What research supports the use of Xenetix 300 in angiography?

The use of Xenetix 300 in angiography is supported by its official regulatory indication. The product is approved for various angiographic procedures, including intravenous digital subtraction angiography, arteriography of the aorta and lower limbs, and angiocardiography.

Q: Are there specific considerations for elderly patients using Xenetix 300?

Official documents advise caution when administering the agent to elderly patients. This is primarily because this population may have underlying conditions, such as existing kidney or cardiovascular issues, which require special attention to manage the risk of acute kidney failure.

Q: Can Xenetix 300 cause a metallic taste in the mouth?

Yes, official documents describing undesirable effects (side effects) associated with Xenetix 300 have noted that a metallic taste in the mouth has been described by some patients. This is listed as a less common reaction.

Q: What is the half-life of Xenetix 300 described as in official sources?

The elimination half-life, which is the time it takes for the body to clear half of the drug, is approximately 1.8 hours in individuals with normal kidney function. This measure confirms the rapid clearance of the active substance, Iobitridol, from the body.

Q: Why do official documents caution against using Xenetix 300 in patients with severe heart failure?

Official warnings regarding severe heart failure are related to the risk of temporary changes in the body's fluid balance caused by the contrast agent. These changes carry a documented risk of potentially inducing conditions like pulmonary edema or worsening existing kidney failure in high-risk patients.

Q: Can Xenetix 300 affect my blood sugar levels?

Official warnings mention that patients with diabetes mellitus are at a higher risk of acute kidney failure when receiving the agent. However, the regulatory documents do not state a direct effect of Xenetix 300 itself on a patient's blood sugar levels or glucose homeostasis.

Q: What are the signs of a severe reaction to Xenetix 300?

Signs of a severe hypersensitivity reaction, which requires immediate medical assistance, include difficulty breathing, swelling of the face, mouth, or throat, and severe low blood pressure. Less common, but extremely serious, reactions can also involve cardiovascular or respiratory distress.

Q: What happens to Xenetix 300 once it has performed its function?

Once the agent has performed its function of enhancing image contrast, the active ingredient (Iobitridol) is designed to be quickly cleared from the body. It is eliminated essentially unchanged, primarily through the process of filtration by the kidneys and excretion in the urine.

Q: Why is it important to stay hydrated after receiving Xenetix 300?

Official guidance emphasizes that adequate hydration before and after the procedure is a key precaution, especially for at-risk patients. This measure supports kidney function and encourages adequate urine output, which assists the body in rapidly eliminating the contrast agent, thereby minimizing the risk of acute kidney issues.

Q: Are there special instructions for women who are breastfeeding and need Xenetix 300?

Yes, regulatory information advises that women who are breastfeeding should temporarily stop breastfeeding for 24 hours after the contrast agent is administered. This is a precautionary measure intended to minimize the amount of the agent that could potentially be passed to the infant.

Q: Is it true that patients should stop certain medications before receiving Xenetix 300?

Yes, regulatory documents describe a requirement to temporarily suspend treatment with the diabetes drug Metformin for a specified period before and after administration. Additionally, co-administration with other medications known to be nephrotoxic (harmful to the kidneys) should be avoided.

Q: Are there specific side effects I should watch out for immediately after receiving Xenetix 300?

Most reactions occur during the injection or within the first hour. Immediate non-severe effects may include a sensation of warmth or flushing and nausea. Patients are typically monitored for at least 30 minutes following the injection to allow for the timely recognition and management of any immediate, more serious reactions, such as anaphylactic shock.

Q: Does having asthma or hay fever make a reaction to Xenetix 300 more likely?

Regulatory precautions advise special caution for patients with asthma, as this condition is associated with an increased documented risk of hypersensitivity reactions to the agent. Patients with any known history of allergy are generally considered to be at a higher risk of reaction than the general population.

Q: Can Xenetix 300 affect thyroid test results?

As an iodinated contrast agent, the product may transiently disrupt the uptake of iodine by the body. This can temporarily reduce the effectiveness of subsequent iodine-based radiopharmaceuticals used for certain thyroid diagnostic or therapeutic procedures.

Q: Is Xenetix 300 ever used outside of hospital or clinic settings?

Regulatory guidelines specify that Xenetix 300 is a specialized diagnostic agent that must be administered exclusively under medical supervision. This is to ensure the procedure is carried out in an appropriate clinical setting equipped to handle potential immediate reactions, aligning with its classification as a professionally administered injectable agent.

Official Storage and Disposal Requirements

Xenetix 300 solution for injection must be stored strictly according to the conditions defined in official regulatory labeling to maintain its stability and quality.

Storage and Disposal Requirement	Official Classification
Temperature and Light	Store protected from light at a temperature below 30 C.
Shelf-Life	The product has a labeled shelf-life of 3 years when stored correctly.
Container and Handling	Must be stored in the original container; require a visual check to ensure the solution is clear and particle-free.
Child Safety	Must be kept out of the sight and reach of children.
Disposal of Unused Product	Any unused portion and waste material must be discarded according to local regulations.

The regulatory profile mandates that the contrast medium maintain a temperature below 30 C and be shielded from light throughout its 3-year shelf-life. Due to its nature as a single-use, sterile solution, any contents remaining after the diagnostic procedure must be disposed of promptly and safely, following local pharmaceutical waste guidelines.